References
- Vogelmeier CF, Criner GJ, Martinez FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary. Am J Respir Crit Care Med. 2017;195(5):557–582. DOI:https://doi.org/10.1164/rccm.201701-0218PP
- Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a systematic analysis for the global burden of disease study 2015. Lancet Respir Med. 2017;5(9):691–706. DOI:https://doi.org/10.1016/s2213-2600(17)30293-x
- Labaki WW, Rosenberg SR. Chronic obstructive pulmonary disease. Ann Intern Med. 2020;173(3):Itc17–itc32. DOI:https://doi.org/10.7326/aitc202008040
- Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3(11):e442. DOI:https://doi.org/10.1371/journal.pmed.0030442
- Wedzicha J-C, Miravitlles M, Hurst JR, et al. Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J. 2017;49(3):1600791(1-16). DOI:https://doi.org/10.1183/13993003.00791-2016
- Suissa S. Inhaled corticosteroids preventing pneumonia mortality: Paradox or selection bias? Eur Respir J. 2019;53(2):1802112(1-5) DOI:https://doi.org/10.1183/13993003.02112-2018
- Lieberman D, Lieberman D, Gelfer Y, et al. Pneumonic vs nonpneumonic acute exacerbations of COPD. Chest. 2002;122(4):1264–1270. DOI:https://doi.org/10.1378/chest.122.4.1264
- Huerta A, Crisafulli E, Menéndez R, et al. Pneumonic and nonpneumonic exacerbations of COPD: inflammatory response and clinical characteristics. Chest. 2013;144(4):1134–1142. DOI:https://doi.org/10.1378/chest.13-0488
- Gómez-Junyent J, Garcia-Vidal C, Viasus D, et al. Clinical features, etiology and outcomes of community-acquired pneumonia in patients with chronic obstructive pulmonary disease. PLoS One. 2014;9(8):e105854. DOI:https://doi.org/10.1371/journal.pone.0105854
- Crisafulli E, Manco A, Ferrer M, et al. Pneumonic versus nonpneumonic exacerbations of chronic obstructive pulmonary disease. Semin Respir Crit Care Med. 2020;41(6):817–829. DOI:https://doi.org/10.1055/s-0040-1702196
- MacDonald MI, Osadnik CR, Bulfin L, et al. Low and high blood eosinophil counts as biomarkers in hospitalized acute exacerbations of COPD. Chest. 2019;156(1):92–100. DOI:https://doi.org/10.1016/j.chest.2019.02.406
- Anthonisen NR, Manfreda J, Warren CP, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med. 1987;106(2):196–204. DOI:https://doi.org/10.7326/0003-4819-106-2-196
- Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis. 2007;44 Suppl 2(Suppl 2):S27–S72. DOI:https://doi.org/10.1086/511159
- Martinez-Garcia MA, Faner R, Oscullo G, et al. Inhaled steroids, circulating eosinophils, chronic airway infection, and pneumonia risk in chronic obstructive pulmonary disease. A network analysis. Am J Respir Crit Care Med. 2020;201(9):1078–1085. DOI:https://doi.org/10.1164/rccm.201908-1550OC
- Thomsen M, Ingebrigtsen TS, Marott JL, et al. Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease. Jama. 2013;309(22):2353–2361. DOI:https://doi.org/10.1001/jama.2013.5732
- Burrows B, Fletcher CM, Heard BE, et al. The emphysematous and bronchial types of chronic airways obstruction. A clinicopathological study of patients in London and Chicago. Lancet. 1966;1(7442):830–835. DOI:https://doi.org/10.1016/S0140-6736(66)90181-4
- Tirlapur VG, Mir MA. Nocturnal hypoxemia and associated electrocardiographic changes in patients with chronic obstructive airways disease. N Engl J Med. 1982;306(3):125–130. DOI:https://doi.org/10.1056/NEJM198201213060301
- Sterne JA, White IR, Carlin JB, et al. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ. 2009;338:b2393. DOI:https://doi.org/10.1136/bmj.b2393
- Stefan MS, Shieh MS, Pekow PS, et al. Trends in mechanical ventilation among patients hospitalized with acute exacerbations of COPD in the United States, 2001 to 2011. Chest. 2015;147(4):959–968. DOI:https://doi.org/10.1378/chest.14-1216
- Segal LN, Martinez FJ. Chronic obstructive pulmonary disease subpopulations and phenotyping. J Allergy Clin Immunol. 2018;141(6):1961–1971. DOI:https://doi.org/10.1016/j.jaci.2018.02.035
- Vedel-Krogh S, Nielsen SF, Lange P, et al. Blood eosinophils and exacerbations in chronic obstructive pulmonary disease. The Copenhagen general population STUDY. Am J Respir Crit Care Med. 2016;193(9):965–974. DOI:https://doi.org/10.1164/rccm.201509-1869OC
- Contoli M, Pauletti A, Rossi MR, et al. Long-term effects of inhaled corticosteroids on sputum bacterial and viral loads in COPD. Eur Respir J. 2017;50(4):1700451(1-10). DOI:https://doi.org/10.1183/13993003.00451-2017
- Pavord ID, Lettis S, Anzueto A, et al. Blood eosinophil count and pneumonia risk in patients with chronic obstructive pulmonary disease: a patient-level Meta-analysis. Lancet Respir Med. 2016;4(9):731–741. DOI:https://doi.org/10.1016/S2213-2600(16)30148-5
- Wynn TA. Type 2 cytokines: mechanisms and therapeutic strategies. Nat Rev Immunol. 2015;15(5):271–282. DOI:https://doi.org/10.1038/nri3831
- Willebrand R, Voehringer D. Regulation of eosinophil development and survival. Curr Opin Hematol. 2017;24(1):9–15. DOI:https://doi.org/10.1097/moh.0000000000000293
- Sridhar S, Liu H, Pham TH, et al. Modulation of blood inflammatory markers by benralizumab in patients with eosinophilic airway diseases. Respir Res. 2019;20(1):14. DOI:https://doi.org/10.1186/s12931-018-0968-8
- Jogdand P, Siddhuraj P, Mori M, et al. Eosinophils, basophils and type 2 immune microenvironments in COPD-affected lung tissue. Eur Respir J. 2020;55(5):1900110(1-14). DOI:https://doi.org/10.1183/13993003.00110-2019
- Shibata S, Miyake K, Tateishi T, et al. Basophils trigger emphysema development in a murine model of COPD through IL-4-mediated generation of MMP-12-producing macrophages. Proc Natl Acad Sci U S A. 2018;115(51):13057–13062. DOI:https://doi.org/10.1073/pnas.1813927115
- Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J. 2005;26(6):1138–1180. DecDOI:https://doi.org/10.1183/09031936.05.00055705
- Suliman HB, Ali M, Piantadosi CA. Superoxide dismutase-3 promotes full expression of the EPO response to hypoxia. Blood. 2004;104(1):43–50. DOI:https://doi.org/10.1182/blood-2003-07-2240
- Barnes PJ. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2016;138(1):16–27. DOI:https://doi.org/10.1016/j.jaci.2016.05.011
- Yeung HM, Hung MW, Fung ML. Melatonin ameliorates calcium homeostasis in myocardial and ischemia-reperfusion injury in chronically hypoxic rats. J Pineal Res. 2008;45(4):373–382. DOI:https://doi.org/10.1111/j.1600-079X.2008.00601.x
- Wang S, Tian S, Li Y, et al. Development and validation of a novel scoring system developed from a nomogram to identify malignant pleural effusion. EBioMedicine. 2020;58:102924. DOI:https://doi.org/10.1016/j.ebiom.2020.102924
- Zheng YM, Li J, Liu S, et al. MRI-Based radiomics nomogram for differentiation of benign and malignant lesions of the parotid gland. Eur Radiol. 2021;31(6):4042–4052. DOI:https://doi.org/10.1007/s00330-020-07483-4